References
Li X, O’Malley BW. Unfolding the action of progesterone receptors. J Biol Chem. 2003;278(41):39261–39264.
Wagenfeld A, Saunders PT, Whitaker L, Critchley HO. Selective progesterone receptor modulators (SPRMs): progesterone receptoraction, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045–1054.
Chabbert-Buffet N, Meduri G, Bouchard P. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307.
Feiteiro J, Mariana M, Verde I, Cairrõo E. Genomic and nonge-nomic effects of mifepristone at the cardiovascular level: a review. Reprod Sci. 2017;24(7):976–988.
Ackerman WE IV, Summerfield TL, Mesiano S, Schatz F, Lockwood CJ, Kniss DA. Agonist-dependent downregulation of progesterone receptors in human cervical stromal fibroblasts. Reprod Sci. 2016;23(1):112–123.
Li CL, Song LP, Tang SY, et al. Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reprod Sci. 2017;24(5):731–737.
Seong SJ, Kim D, Lee KH, et al. Role of hormone therapy after primary surgery for endometrioma: a multicenter retrospective cohort study. Reprod Sci. 2016;23(8):1011–1018.
Kannan A, Bhurke A, Sitruk-Ware R, et al. Characterization of molecular changes in endometrium associated with chronic use of progesterone receptor modulators: ulipristal acetate versus mife-pristone. Reprod Sci. 2018;25(3):320–328.
Lee SR, Yi KW, Song JY, et al. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod Sci. 2018;25(3):341–346.
Rights and permissions
About this article
Cite this article
Maduro, M.R. A Look Into the Promising World of Selective Progesterone Receptor Modulators. Reprod. Sci. 25, 309–310 (2018). https://doi.org/10.1177/1933719118758070
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719118758070